Immunotherapy: an alternative promising therapeutic approach against cancers.
Sneh Lata GuptaSrijani BasuVijay SoniRishi Kumar JaiswalPublished in: Molecular biology reports (2022)
The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus.
Keyphrases
- cell therapy
- papillary thyroid
- combination therapy
- clinical trial
- monoclonal antibody
- squamous cell
- cancer therapy
- dna damage
- lymph node metastasis
- squamous cell carcinoma
- drug delivery
- randomized controlled trial
- bone marrow
- young adults
- single cell
- oxidative stress
- cell proliferation
- replacement therapy
- double blind
- smoking cessation